Posts tagged ‘ALK’
February 7th, 2011
Sally Church on Pharma Strategy Blog reviews a 2011 paper on molecular subsets in lung cancer published by Lowly & Carbonne in Nature Reviews Clinical Oncology.
The molecular subsets to-date include KRAS, EGFR and ALK, but what is interesting is that half remain unknown.
You can read Sally’s blog post for her thoughts on what the next target may be after ALK and crizotinib.
November 30th, 2010
Published by Sally Church on Pharma Strategy Blog